Duac™Once Daily Gel — Competitive Intelligence Brief

Duac™Once Daily Gel (Duac™Once Daily Gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic combination. Area: Dermatology.

phase 3 Topical antibiotic combination Bacterial 50S ribosome (clindamycin); non-specific oxidative antimicrobial (benzoyl peroxide) Dermatology Small molecule

Target snapshot

Duac™Once Daily Gel (Duac™Once Daily Gel) — GlaxoSmithKline. Duac combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and decrease inflammation in acne lesions.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Duac™Once Daily Gel TARGET	Duac™Once Daily Gel	GlaxoSmithKline	phase 3	Topical antibiotic combination	Bacterial 50S ribosome (clindamycin); non-specific oxidative antimicrobial (benzoyl peroxide)
Acnatac® Gel right face	Acnatac® Gel right face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Duac® fixed dose combination gel	Duac® fixed dose combination gel	GlaxoSmithKline	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Acnatac® Gel left face	Acnatac® Gel left face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide)
BENZOYL PEROXIDE/ CLINDAMYCIN	BENZOYL PEROXIDE/ CLINDAMYCIN	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
clindamycin 1% / benzoyl peroxide 5% tube	clindamycin 1% / benzoyl peroxide 5% tube	Sanofi	marketed	Topical antibiotic combination	Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Polysporin Triple	Polysporin Triple	University Health Network, Toronto	marketed	Topical antibiotic combination	Bacterial cell wall (bacitracin), bacterial ribosome (neomycin), bacterial cell membrane (polymyxin B)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic combination class)

1. Stiefel, a GSK Company · 3 drugs in this class
2. GlaxoSmithKline · 3 drugs in this class
3. GWT-TUD GmbH · 2 drugs in this class
4. Sun Pharmaceutical Industries, Inc. · 1 drug in this class
5. University Health Network, Toronto · 1 drug in this class
6. University of British Columbia · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. B. Braun Medical SA · 1 drug in this class
9. Watson Laboratories, Inc. · 1 drug in this class
10. Padagis LLC · 1 drug in this class